Surgery Partners, Inc. (SGRY), a prominent player in the U.S. healthcare sector, stands at an intriguing crossroads for investors. With a market capitalization of $2.1 billion, this Brentwood, Tennessee-based company specializes in operating a network of surgical facilities, focusing on non-emergency procedures across various disciplines such as orthopedics, ophthalmology, gastroenterology, and more. The company’s strategic emphasis on ambulatory surgery centers and surgical hospitals positions it well within the medical care facilities industry.
Currently trading at $16.03, Surgery Partners’ stock has experienced a relatively stable performance with a 52-week range between $11.49 and $23.84. The stock’s recent price change was a minimal 0.04 (0.00%), indicating a period of consolidation. However, what makes the stock particularly interesting is its potential upside of 14.84%, as indicated by the average target price of $18.41 from analysts.
The valuation metrics for Surgery Partners present a mixed picture. While the trailing P/E ratio and PEG ratio are not available, the forward P/E ratio stands at 24.50, suggesting that the stock is priced for future growth. The absence of a P/E ratio and other traditional valuation metrics like Price/Book and EV/EBITDA might be a point of concern for some investors, but it can also indicate the potential for unrecognized value.
Performance metrics reveal a revenue growth of 4.50%, which, although modest, demonstrates the company’s ability to maintain steady expansion in a competitive market. However, the negative earnings per share (EPS) of -0.59 and the absence of net income suggest profitability challenges. Despite these hurdles, the company has managed a positive return on equity of 2.75% and boasts a robust free cash flow of approximately $199 million, underscoring its operational efficiency and potential to fund growth initiatives.
From a dividend perspective, Surgery Partners does not currently offer a yield, with a payout ratio of 0.00%. This may appeal to investors focused on capital appreciation rather than income generation.
Analyst sentiment towards Surgery Partners is predominantly positive, with 9 buy ratings and 3 hold ratings, and no sell ratings. This favorable outlook reflects confidence in the company’s strategic direction and market positioning. The target price range spans from $14.00 to $24.00, with the current price offering a potential upside that adds to its investment appeal.
Technical indicators provide additional insights into the stock’s trajectory. The 50-day moving average of $14.85 and the 200-day moving average of $15.68 suggest that the stock is trading above its recent trend lines, a positive technical signal. The Relative Strength Index (RSI) of 59.34 indicates that the stock is neither overbought nor oversold, positioning it neutrally in terms of momentum. The MACD at 0.36, with a signal line of 0.50, further supports a cautious optimism about the stock’s short-term performance.
As Surgery Partners continues to navigate the complexities of the healthcare landscape, its focus on specialized, non-emergency surgical services could provide a sustained competitive edge. For investors seeking exposure to the healthcare sector with a growth-oriented company, Surgery Partners, Inc. offers a compelling proposition with a significant potential upside and a strong buy consensus from analysts.
